Trials / Not Yet Recruiting
Not Yet RecruitingNCT06920420
Novel Biomarkers Related Xuebijing Injection Improves Sepsis
Xuebijing Injection Regulates Endothelial Cell Panapoptosis in Treating Sepsis Through PCDHAC2/BAX/AIM2 Pathway
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Southeast University, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, posing a serious threat to human health. The study demonstrated that hemopexin injection significantly reduced the 28-day all-cause mortality rate of sepsis patients, and this study clarified the specific target and molecular mechanism of hemopexin injection in the treatment of sepsis, which may be of great scientific significance and clinical value for the precise treatment of sepsis and the research and development of new drugs.
Conditions
Timeline
- Start date
- 2025-03-30
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
- First posted
- 2025-04-09
- Last updated
- 2025-04-09
Source: ClinicalTrials.gov record NCT06920420. Inclusion in this directory is not an endorsement.